Investment firm Chicago Capital, LLC has significantly increased its investment in Procept Biorobotics, according to an SEC filing dated October 22, 2025. The firm acquired an additional 999,873 shares, boosting its total holdings to 1,568,845 shares. This substantial position was valued at $55.99 million at the end of the previous quarter. This move represents a massive increase in Chicago Capital's stake, signaling a strong belief in the surgical robotics company's future prospects. Procept Biorobotics specializes in developing minimally invasive robotic solutions, such as its AquaBeam Robotic System, for treating benign prostatic hyperplasia (BPH). The significant investment is a noteworthy event for the healthcare technology firm, especially given the stock was down 48.57% year-over-year as of October 21, 2025.